T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
The proteins that make cell-to-cell cargo transport possible. ScienceDaily . Retrieved February 12, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250115165210.htm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback